查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1540902

2024-2032 年反义和 RNAi 治疗市场报告（按技术、给药途径、应用和地区）

Antisense & RNAi Therapeutics Market Report by Technology, Route of Administration, Application, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球反义和RNAi治疗市场规模达17亿美元。全球遗传疾病和慢性病盛行率不断上升，推动该市场正在经历稳定成长，这需要创新的治疗方法、主要市场的支持性监管环境以加速新疗法的批准和商业化，以及药物输送系统的持续技术进步。

反义和 RNAi 治疗市场分析：

主要市场驱动因素：市场由强大的技术驱动因素驱动，例如药物传输系统的快速进步，增加了对细胞的治疗影响和靶向特异性，以及遗传性疾病和慢性疾病的高发病率，这需要使用尖端技术治疗方式。

主要市场趋势：反义和 RNAi 治疗行业的主要趋势之一是其与基于独特基因谱并旨在改善患者治疗结果的个人化医疗紧密相关。

地理趋势：根据反义和RNAi治疗市场分析，北美由于其优良的医疗基础设施、高医疗支出和友善的监管环境，在反义和RNAi治疗市场占据主导地位。

竞争格局：这是一个充满活力的市场，拥有许多传统药品市场参与者，例如顶级製药公司和已经确立地位的创新者。竞争空间必须决定自有技术的专利之争、获得监管机构的批准以及进行新的合作。

挑战与机会：反义和RNAi疗法市场研究报告显示，该产业的主要挑战是开发和管理RNAi和反义疗法的高成本和复杂性。后者也是一个机会，因为它将将该行业转变为创新和低成本药物发现的场所，从而在未经治疗的遗传疾病方面取得突破。

反义和 RNAi 治疗市场趋势：

药物输送系统的技术进步

在这个市场中，主要驱动力之一是药物传递方法的持续发展。这些技术使 RNA 分子能够以避免降解的方式干净且有效地递送到相关细胞，从而提高治疗效果。例如，脂质奈米颗粒和缀合物技术使以前可以忽略不计的细胞摄取和反义寡核苷酸或 siRNA 的平衡成为可能。它增加了递送，同时增强了治疗方法适合针对特定人体物质的相似程度，这对于癌症、疾病和病毒感染等至关重要。反义和 RNAi 疗法市场预测显示这些疗法将获得大量研究关注和财务投资。例如，诺华于 2023 年 7 月收购了 DTx Pharma，这是一家专注于神经科学适应症的短干扰 RNA 疗法的生物技术公司。同样，这些收购正在创造积极的市场前景。

遗传性疾病和慢性病的盛行率不断增加

遗传疾病和慢性病在大众中发病率的不断上升极大地支持了反义和 RNAi 治疗市场的成长。亨廷顿氏舞蹈症、某些类型的癌症和广泛的遗传性疾病只是缺乏有效治疗方法的流行疾病的几个例子，这创造了对反义和 RNAi 疗法的需求。除此之外，反义和 RNAi 治疗方案作为候选疾病易感基因的抑制因子提供了一条新途径。一方面，新药最有可能进入临床。另一方面，它们具有针对特定基因的能力，为目前使用传统药理学方法无法控制的患者提供了一种新的治疗方式。这反过来又明确需要持续投资新的生物製药研发项目。

新疗法的支持性监管环境

支持性监管环境推动了反义和 RNAi 疗法的需求。例如，2023 年 10 月，美国食品药物管理局孤儿产品开发办公室宣布为 2024 财年 (FY) 提供资金，以帮助承担对罕见疾病和病症进行自然史研究的费用。该 RFA 的既定目标是「提高科学严谨性和合作，造福罕见疾病或病症患者」。此外，FDA 和 EMA 等全球卫生当局正在为任何新疗法引入更快的审查流程，包括 RNAi 和反义技术。同时，孤儿药地位、加速审批和优先审评券等监管激励措施变得更加重要，因为它们让製药公司更有动力致力于反义和 RNAi 疗法的开发。

反义和 RNAi 治疗市场细分：

IMARC Group提供了每个细分市场的主要趋势分析，以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据技术、给药途径和应用对市场进行了分类。

按技术划分：

RNA干扰

siRNA

miRNA

反义RNA

反义RNA占反义和RNAi治疗市场的大部分份额

该报告基于该技术对市场进行了详细的细分和分析。这包括 RNA 干扰（siRNA 和 miRNA）和反义 RNA。根据反义和 RNAi 治疗市场报告，反义 RNA 代表了最大的部分。

反义RNA技术因其成熟的方法论和最长的临床应用历史而成为反义和RNAi治疗市场的领导者。反义 RNA 是基于附着于特定 mRNA 序列的合成 RNA 分子发挥作用，并导致对导致疾病的目标基因的封锁。此外，从遗传病理学到包括癌症在内的各种来源的慢性疾病的最广泛的应用范围主要确保了其领先地位。除此之外，与其他 RNAi 技术不同的是，这些领先技术已经花费了长达两年的广泛使用时间，这使得在研究和开发行动和交付机制方面投入了大量资源。此外，一些反义治疗剂已进入RNAi技术市场，并已在FDA积极註册，最终证实了它们的有效性并鼓励进一步投资。所有这些因素都有助于确保钻探的稳定性和最重要的份额；更重要的是，在反义子领域可以观察到已经申请扩散的有前途的药物。因此，该技术引领了基于RNA的治疗市场，并为该领域的突破奠定了基础。

依给药途径分类：

静脉途径

皮下途径

鞘内途径

肺部输送

腹腔注射

其他的

肺部输送占产业最大份额

反义和 RNAi 疗法市场报告还提供了基于给药途径的详细市场细分和分析。这包括静脉途径、皮下途径、鞘内途径、肺部递送、腹膜内注射等。根据该报告，肺部递送占据最大的反义和 RNAi 治疗市场。

在反义和RNAi治疗市场中，肺部递送在给药管道方面处于领先地位。有几个理由，包括直接用于治疗呼吸系统疾病，其中局部输送显着提高了有效性。因此，进入肺部并携带治疗剂的能力可有效治疗呼吸道合胞病毒和肺动脉高压等疾病以及针对肺癌。它使疾病部位的溶液浓度高，限制了全身性，因此副作用较低，提高了患者的依从性和治疗的整体有效性。此外，能够将药物有效输送到肺组织的创新吸入器和解决方案也是一个重要方面。由于负荷不断增加，我们面临着使治疗尽可能有效和有针对性的压力。因此，肺部递送成为RNAi技术市场的重点发展重点，并主导着整体投资和创新份额。

按应用划分：

肿瘤学

心血管疾病 (CVD)

呼吸系统疾病

肾臟疾病

神经退化性疾病

遗传性疾病

传染病

其他的

该报告根据应用程式提供了详细的市场细分和分析。这包括肿瘤学、心血管疾病 (CVD)、呼吸系统疾病、肾臟疾病、神经退化性疾病、遗传性疾病、传染病等。

按地区划分：

北美洲

美国

加拿大

亚太

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美市场领先，占据最大的反义和RNAi治疗市场份额

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。根据该报告，北美是反义和 RNAi 治疗药物最大的区域市场。

北美是反义和 RNAi 治疗市场最大的区域市场。这一突出地位主要归功于该地区成熟的生物技术和製药研究基础设施。此外，各国政府和其他全球卫生组织前所未有的支持为反义和 RNAi 治疗平台所需的研究和先进开发创造了有利的环境。根据反义和RNAi治疗市场分析，该地区多家领先的生物技术和製药公司的存在，创造了激烈的竞争并促进了创新，加速了发展机会和产品的推出。此外，北美积极主动的监管环境以及 FDA 的特殊参与（FDA 已快速追踪许多用于治疗多种遗传和慢性疾病的 RNA 药物）为 RNA 治疗市场提供了支持。此外，该地区目标疾病（包括癌症和遗传性疾病）的高盛行率创造了反义和 RNAi 疗法的需求。因此，北美作为技术开发的主导者以及基于 RNA 的治疗产品的主要市场，引领着反义和 RNAi 治疗市场。

本报告回答的关键问题

  • 全球反义和RNAi治疗市场有多大？ 2024-2032年全球反义和RNAi治疗市场的预期成长率是多少？
  • 推动全球反义和 RNAi 治疗市场的关键因素是什么？
  • COVID-19 对全球反义和 RNAi 治疗市场有何影响？
  • 基于此技术的全球反义和 RNAi 治疗市场的细分情况如何？
  • 根据给药途径，全球反义和 RNAi 治疗市场的细分情况如何？
  • 全球反义和RNAi治疗市场的关键区域有哪些？
  • 全球反义和 RNAi 治疗市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球反义与 RNAi 治疗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依技术

  • RNA干扰
    • 市场趋势
    • 关键环节
      • siRNA
      • miRNA
    • 市场预测
  • 反义RNA
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依管理途径

  • 静脉途径
    • 市场趋势
    • 市场预测
  • 皮下途径
    • 市场趋势
    • 市场预测
  • 鞘内途径
    • 市场趋势
    • 市场预测
  • 肺部输送
    • 市场趋势
    • 市场预测
  • 腹腔注射
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按应用

  • 肿瘤学
    • 市场趋势
    • 市场预测
  • 心血管疾病 (CVD)
    • 市场趋势
    • 市场预测
  • 呼吸系统疾病
    • 市场趋势
    • 市场预测
  • 肾臟疾病
    • 市场趋势
    • 市场预测
  • 神经退化性疾病
    • 市场趋势
    • 市场预测
  • 遗传性疾病
    • 市场趋势
    • 市场预测
  • 传染病
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Alnylam Pharmaceuticals Inc.
    • Arbutus Biopharma Corporation
    • Arrowhead Pharmaceuticals Inc.
    • Benitec Biopharma Ltd.
    • Bio-Path Holdings Inc.
    • Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
    • Ionis Pharmaceuticals Inc.
    • OliX Pharmaceuticals Inc.
    • Phio Pharmaceuticals Corp.
    • Sarepta Therapeutics Inc.
    • Silence Therapeutics
    • Sirnaomics Inc.
Product Code: SR112024A6549

The global antisense & RNAi therapeutics market size reached US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.25% during 2024-2032. The market is experiencing steady growth driven by the increasing prevalence of genetic and chronic diseases globally necessitates innovative treatments, supportive regulatory environments across major markets to expedite the approval and commercialization of new therapies, and continuous technological advancements in drug delivery systems.

Antisense & RNAi Therapeutics Market Analysis:

Major Market Drivers: The market is driven by powerful technological drivers such as rapid advancements in drug delivery systems, which increased therapeutic impact on cells and targeting specificity, and a high incidence of genetic disorders and chronic diseases, which requires the use of cutting-edge therapeutic modalities.

Key Market Trends: One of the major antisense & RNAi therapeutics industry trends is its tight association with the personalization of medicine based on unique genetic profiles and aimed at improving patient outcomes.

Geographical Trends: According to the antisense & RNAi therapeutics market analysis, North America dominates the market for Antisense & RNAi Therapeutics due to its excellent healthcare infrastructure, high healthcare spending, and friendly regulatory environment.

Competitive Landscape: This is a dynamic market with a pool of traditional drug market players such as top pharmaceutical companies and innovators that have established themselves. The competitive space will have to determine the battle for patents of owned technologies, achieving the green light from the regulatory authorities, and making new collaborations.

Challenges and Opportunities: The antisense & RNAi therapeutics market research report shows that the industry's major challenge is the high cost and complexity of developing and managing RNAi and antisense-based therapies. The latter is also an opportunity since it will transform the sector into loci of innovation and low-cost drug discovery resulting in breakthroughs in untreated genetic diseases.

Antisense & RNAi Therapeutics Market Trends:

Technological advancements in drug delivery systems

In this market, one of the major drivers is the continuing developments of drug delivery methods. These technologies allow RNA molecules to be delivered to relevant cells cleanly and efficiently, in a pattern that avoids degradation and hence provided enhanced efficacy in terms of therapy. For example, lipid nanoparticles and conjugate technologies enabled the previously negligible cellular uptake and balance of antisense oligonucleotides or siRNA. It increases delivery while enhancing the degree of similarity in which therapeutics are suitable to target specific human material, which is critical in cancer, disorders, and viral infections, among other things. The antisense & RNAi therapeutics market forecast indicates that these treatments will gain substantial research attention and financial investment. For instance, Novartis acquired DTx Pharma in July 2023, which is a biotechnology company concentrating on short-interfering RNA therapy for neuroscience indications. Similarly, these acquisitions are creating a positive market outlook.

Increasing prevalence of genetic disorders and chronic diseases

The accelerating incidences of genetic and chronic diseases among the masses is significantly supporting the antisense & RNAi therapeutics market growth. Huntington's, certain types of cancer, and a wide range of hereditary genetic conditions are just a few examples of prevalent illnesses with few efficient treatments, which create demand for antisense & RNAi therapeutics. Along with this, Antisense and RNAi treatment options provide a new avenue as candidate disease-predisposing genes' repressors. On one hand, the new drugs have the best prospects of being included in clinical practice. On the other - by having the ability to target specific genes, they represent a new treatment modality for patients with conditions that are currently unmanageable using conventional pharmacological methods. This, in turn, generates a clear need for continued investment in new biopharmaceutical R&D projects.

Supportive regulatory environment for novel therapies

The antisense & RNAi therapeutics demand is impelled by the supportive regulatory environment. For instance, in October 2023, The Food and Drug Administration's Office of Orphan Products Development announced the availability of funds for fiscal year (FY) 2024 to help underwrite the costs of conducting natural history studies on rare diseases and conditions. The stated goal of this RFA is "to advance scientific rigor and collaboration for the benefit of patients with rare diseases or conditions." In addition, global health authorities, such as the FDA and EMA, are introducing faster review processes for any new therapies, inclusive of RNAi and antisense technology. Meanwhile, regulatory incentives like orphan drug status, accelerated approval, and priority review vouchers gain even more relevance since they give pharmaceutical companies even more incentive to put effort into the development of antisense and RNAi therapies.

Antisense & RNAi Therapeutics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on technology, route of administration and application.

Breakup by Technology:

RNA Interference

siRNA

miRNA

Antisense RNA

Antisense RNA accounts for the majority of the antisense & RNAi therapeutics market share

The report has provided a detailed breakup and analysis of the market based on the technology. This includes RNA Interference(siRNA, and miRNA), and Antisense RNA. According to the antisense & RNAi therapeutics market report, Antisense RNA represented the largest segment.

Antisense RNA technology is the leader in the Antisense & RNAi Therapeutics market due to its mature methodology and the longest history of clinical application. Antisense RNA acts based on synthetic RNA molecules adhering to specific mRNA sequences, and it results in the blockade of target genes responsible for disease. In addition, the broadest possible range of applications from genetic pathologies to chronic diseases of various origins, including cancer, primarily has ensured its leader position. Apart from this, unlike other RNAi technologies, the leaders have already spent up to two years of widespread use, which allowed the investment of large resources in research and developing mechanisms of action and delivery. Moreover, some antisense therapeutic agents are already on the RNAi technology market with active FDA registration, which ultimately confirms their effectiveness and encourages further investment. All these factors contribute to ensuring a steady drill with the most significant share; even more, promising drugs already filed to proliferation can be observed in the antisense subfield. Thus, this technology leads the RNA based therapeutics market and lays the foundation for breakthroughs in this field.

Breakup by Route of Administration:

Intravenous Route

Subcutaneous Route

Intrathecal Route

Pulmonary Delivery

Intraperitoneal Injection

Others

Pulmonary delivery holds the largest share of the industry

A detailed breakup and analysis of the market based on the route of administration have also been provided in the antisense & RNAi therapeutics market report. This includes intravenous route, subcutaneous route, intrathecal route, pulmonary delivery, intraperitoneal injection, and others. According to the report, pulmonary delivery accounted for the largest antisense & RNAi therapeutics market share.

In the Antisense & RNAi therapeutics market, pulmonary delivery has taken the lead in terms of administration channels. There are several justifications, including direct utilization in curing respiratory conditions, in which localized delivery significantly increases the effectiveness. Thus, the ability to access the lungs and carry therapeutic agents is effective in treating diseases such as respiratory syncytial virus and pulmonary arterial hypertension as well as directing to lung cancer. It enabled high concentration of the solution on the site of the disease, limited systemic, hence lower side effects, improved patient adherence, and the overall effectiveness of treatment. Moreover, innovative inhalers and solutions that allow efficient drug delivery to lung tissues are also an important aspect. Due to the increasing load, there is pressure to make therapy as effective and targeted as possible. Therefore, pulmonary delivery serves as a key development focus of the RNAi technology market and directs the overall investment and innovation quotas.

Breakup by Application:

Oncology

Cardiovascular Diseases (CVDs)

Respiratory Disorders

Renal Diseases

Neurodegenerative Disorders

Genetic Disorders

Infectious Diseases

Others

The report has provided a detailed breakup and analysis of the market based on the application. This includes oncology, cardiovascular diseases (CVDs), respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and others.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest antisense & RNAi therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for antisense & RNAi therapeutics.

North America is the largest regional segment in the Antisense & RNAi therapeutics market. This prominence is primarily due to the region's mature biotechnological and pharmaceutical research infrastructure. Additionally, unprecedented support from various national governments and other global health organizations has created a conducive environment for research and the advanced development required to progress antisense and RNAi therapy platforms. According to the antisense & RNAi therapeutics market analysis, the presence of several leading biotech and pharmaceutical companies in the region, which has created fierce competition and promoting innovation, has accelerated development opportunities as well as product launch. Additionally, North America's proactive regulatory environment, the exceptional participation of the FDA, which has fast-tracked many RNA-based drugs for several genetic and chronic disease conditions, supports the RNA based therapeutics market. Moreover, the high prevalence of target diseases, including cancer and genetic disorders, in the region creates antisense & RNAi therapeutics demand. Thus, North America leads the Antisense & RNAi Therapeutics market, as a dominant player in technology development and also as the primary market for RNA-based therapeutic products.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the antisense & RNAi therapeutics industry include:

Alnylam Pharmaceuticals Inc.

Arbutus Biopharma Corporation

Arrowhead Pharmaceuticals Inc.

Benitec Biopharma Ltd.

Bio-Path Holdings Inc.

Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)

Ionis Pharmaceuticals Inc.

OliX Pharmaceuticals Inc.

Phio Pharmaceuticals Corp.

Sarepta Therapeutics Inc.

Silence Therapeutics

Sirnaomics Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The major players in the market are increasingly involved in research and development to diversify their genetic therapy portfolios. They are actively engaging in strategic partnerships, taking over small biotech companies, or collaborating with academic institutions and R&D centers to capitalize on emerging and disruptive technologies and fast-track drug development. In confluence with this, considering the high costs and development risks, companies make significant investments in clinical trials to guarantee their effectiveness and safety in a wider applications portfolio, especially in AlNM diseases. Collaboration with the regulatory bodies enhances the companies' competitive performance and guides them along the way to bring new drugs faster. This initiative is vital for creating competitive advantages and a positive antisense & RNAi therapeutics market outlook.

Antisense & RNAi Therapeutics Market News:

April 08, 2024: OliX Pharmaceuticals Inc., a leading developer of RNA interfering therapeutics in the treatment area of severe diseases including fibro-inflammatory and metabolic diseases, disclosed that the Company has gotten approval from the Alfred Human Research Ethics Committee to commence the Phase 1 clinical trial of drug candidate OLX75016 (candidate of OLX702A for NASH treatment).

June 21, 2023: Arbutus Biopharma Corporation provided the first data from the empirical study on RNA interference therapy, nucleos(t)ide analogue (NA), and pegylated interferon alfa-2a therapy in patients with chronic hepatitis B virus at the EASL Conference 2023.

Key Questions Answered in This Report

  • 1. How big is the global antisense & RNAi therapeutics market?
  • 2. What is the expected growth rate of the global antisense & RNAi therapeutics market during 2024-2032?
  • 3. What are the key factors driving the global antisense & RNAi therapeutics market?
  • 4. What has been the impact of COVID-19 on the global antisense & RNAi therapeutics market?
  • 5. What is the breakup of the global antisense & RNAi therapeutics market based on the technology?
  • 6. What is the breakup of the global antisense & RNAi therapeutics market based on the route of administration?
  • 7. What are the key regions in the global antisense & RNAi therapeutics market?
  • 8. Who are the key players/companies in the global antisense & RNAi therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antisense & RNAi Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 RNA Interference
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 siRNA
      • 6.1.2.2 miRNA
    • 6.1.3 Market Forecast
  • 6.2 Antisense RNA
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Intravenous Route
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Subcutaneous Route
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intrathecal Route
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pulmonary Delivery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Intraperitoneal Injection
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cardiovascular Diseases (CVDs)
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Respiratory Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Renal Diseases
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Neurodegenerative Disorders
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Genetic Disorders
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Infectious Diseases
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast
  • 8.8 Others
    • 8.8.1 Market Trends
    • 8.8.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Alnylam Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Arbutus Biopharma Corporation
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Arrowhead Pharmaceuticals Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Benitec Biopharma Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bio-Path Holdings Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Ionis Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 OliX Pharmaceuticals Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Phio Pharmaceuticals Corp.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Sarepta Therapeutics Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Silence Therapeutics
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
    • 14.3.12 Sirnaomics Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Antisense & RNAi Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Antisense & RNAi Therapeutics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Antisense & RNAi Therapeutics Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: Antisense & RNAi Therapeutics Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Antisense & RNAi Therapeutics Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Antisense & RNAi Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Antisense & RNAi Therapeutics (RNA Interference) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Antisense & RNAi Therapeutics (RNA Interference) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Antisense & RNAi Therapeutics (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Antisense & RNAi Therapeutics (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Antisense & RNAi Therapeutics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Antisense & RNAi Therapeutics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: North America: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: North America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: United States: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: United States: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Canada: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Canada: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Asia-Pacific: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Asia-Pacific: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: China: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: China: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Japan: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Japan: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: India: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: India: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: South Korea: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: South Korea: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Australia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Australia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Indonesia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Indonesia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Europe: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Europe: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Germany: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Germany: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: France: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: France: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: United Kingdom: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: United Kingdom: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Italy: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Italy: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Spain: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Spain: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Russia: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Russia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Latin America: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Latin America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Brazil: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Brazil: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Mexico: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Mexico: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Middle East and Africa: Antisense & RNAi Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Middle East and Africa: Antisense & RNAi Therapeutics Market: Breakup by Country (in %), 2023
  • Figure 88: Middle East and Africa: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Global: Antisense & RNAi Therapeutics Industry: SWOT Analysis
  • Figure 90: Global: Antisense & RNAi Therapeutics Industry: Value Chain Analysis
  • Figure 91: Global: Antisense & RNAi Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antisense & RNAi Therapeutics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 3: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Antisense & RNAi Therapeutics Market: Competitive Structure
  • Table 7: Global: Antisense & RNAi Therapeutics Market: Key Players